Skip to main content

Advertisement

Table 2 Characteristics associated with MSM achieving viral suppression in the first year of treatment

From: Predictors of viral suppression and rebound among HIV-positive men who have sex with men in a large multi-site Canadian cohort

Characteristic Viral Suppression , n (%)
No (n = 410) Yes (n = 2448) P-value
Province
 British Columbia 140 (34) 714 (29) 0.011
 Ontario 158 (39) 887 (36)
 Quebec 112 (27) 847 (35)
Age (years) 38 (33–44) 40 (34–46) 0.002
Ethnicity
 Caucasian 216 (53) 1104 (45) 0.002
 Black 8 (2) 43 (2)
 Aboriginal 17 (4) 53 (2)
 Other 40 (10) 331 (14)
 Unknown 129 (31) 917 (37)
History of IDU
 No 336 (82) 2219 (91) <0.001
 Yes 60 (15) 187 (8)
 Unknown 14 (3) 42 (2)
Hepatitis C status
 No 321 (78) 2092 (85) 0.001
 Yes 68 (17) 263 (11)
 Unknown 21 (5) 93 (4)
Era of cART initiation
 2000–2003 152 (37) 577 (24) <0.001
 2004–2007 127 (31) 804 (33)
 2008–2012 131 (32) 1067 (44)
Number of viral load tests per year
 Less than 3 115 (28) 468 (19) <0.001
 3–4 188 (46) 1402 (57)
 5–6 48 (12) 312 (13)
 More than 6 59 (14) 266 (11)
Initial 3rd ARV class
 NNRTI 140 (34) 1137 (46) <0.001
 Unboosted PI 39 (10) 89 (4)
 Boosted PI 194 (47) 1045 (43)
 Other 37 (9) 177 (7)
Initial 3rd ARV
 Nevirapine 41 (10) 211 (9) <0.001
 Efavirenz 105 (26) 928 (38)
 Lopinavir 73 (18) 351 (14)
 Atazanavir 79 (19) 499 (20)
 Other 112 (27) 459 (19)
NRTI combination
 Tenofovir/emtricitabine 134 (33) 1083 (44) <0.001
 Zidovudine/lamivudine 114 (28) 480 (20)
 Tenofovir/lamivudine 27 (7) 180 (7)
 Abacavir/lamivudine 58 (14) 410 (17)
 Stavudine/lamivudine 43 (10) 169 (7)
 Other 34 (8) 126 (5)
AIDS-defining illness
 No 307 (75) 1977 (81) 0.006
 Yes 88 (21) 371 (15)
 Unknown 15 (4) 100 (4)
Viral load (log10 copies/mL) 5.00 (4.75–5.00) 4.93 (4.48–5.00) <0.001
CD4 count (cells/uL) 190 (100–310) 231 (134–327) 0.001